查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1606698

糖尿病腎臟病變治療市場：按治療類型、最終用戶分類 - 全球預測 2025-2030

Diabetic Nephropathy Treatment Market by Treatment Type (End-stage Renal Disease (ESRD) Treatment, Medications, Pharmacological Treatment), End-User (Hospitals, Nephrology Clinics) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年糖尿病腎臟病變治療市場價值為22.6億美元，預計到2024年將達到23.8億美元，複合年成長率為5.46%，到2030年將達到32.8億美元。

糖尿病腎臟病變的治療，血管收縮素轉化酵素（ACE）抑制劑、血管收縮素II受體阻斷劑（ARB）、鈉-葡萄糖共同輸送體-2（SGLT2）抑制劑等藥物用於併發症。這些治療的需求源於全球糖尿病盛行率的不斷上升，推動了對有效干預措施的巨大需求，以防止進展為末期腎病。主要用途包括減少蛋白尿、抑制腎功能下降和控制併發症。最終使用者主要是醫院、腎臟病診所和研究機構。該市場主要受到糖尿病人口成長、藥物開發進步以及對早期診斷日益關注的影響。在對疾病病理生理學和遺傳傾向的新見解的推動下，新型生技藥品和精準醫學代表著巨大的商機。然而，它也存在治療成本高、潛在副作用和監管程序複雜等限制。此外，低收入地區的醫療保健系統多種多樣，可近性問題也是市場成長的問題。創新可能會在開發對患者友好的配方（例如每週一次的口服藥物）以及用於即時病患監測的數位健康解決方案的整合方面蓬勃發展。此外，針對多種途徑的聯合治療的研究可能會提高治療效果。市場的本質是高度動態和競爭的，主要製藥公司都優先考慮研發以保持競爭優勢。從策略上講，研究和臨床測試合作和聯盟可以在克服現有挑戰和進入開拓市場方面發揮至關重要的作用。透過專注於以患者為中心的進步並利用技術整合，公司可以在糖尿病腎臟病變治療領域佔據有利地位。

主要市場統計
基準年[2023] 22.6億美元
預測年份 [2024] 23.8億美元
預測年份 [2030] 32.8億美元
複合年成長率（%） 5.46%

市場動態：揭示快速發展的糖尿病腎臟病變治療市場的關鍵市場洞察

供需的動態交互作用正在改變糖尿病腎臟病變治療市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 由於老年人口的增加，全球糖尿病盛行率不斷上升
    • 政府主導努力解決糖尿病及其併發症的負擔
    • 越來越重視以病人為中心的糖尿病腎臟病護理計劃
  • 市場限制因素
    • 糖尿病腎臟病變治療費用高
  • 市場機會
    • 採用新的、更有效的糖尿病腎臟病變治療方法
    • 完善糖尿病腎臟病變治療報銷政策與醫療應用
  • 市場問題
    • 糖尿病腎臟病變相關的合併症和治療複雜性

波特五力：駕馭糖尿病腎臟病變治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解糖尿病腎臟病變治療市場的外部影響

外部宏觀環境因素在塑造糖尿病腎臟病變治療市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解糖尿病腎臟病變治療市場的競爭格局

對糖尿病腎臟病變治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：糖尿病腎臟病變治療市場供應商的績效評估

FPNV定位矩陣是評估糖尿病腎臟病變治療市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：制定糖尿病腎臟病變治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對糖尿病腎臟病治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3. 塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 隨著人口老化的加劇，全球糖尿病盛行率正在上升
      • 政府主導努力解決糖尿病及其併發症的負擔
      • 以患者為中心的糖尿病腎臟病護理計劃變得越來越重要
    • 抑制因素
      • 糖尿病腎臟病變治療費用上漲
    • 機會
      • 採用新的、更有效的糖尿病腎臟病治療方法
      • 完善糖尿病腎臟病變治療報銷保單和醫療保險
    • 任務
      • 糖尿病腎臟病變相關的併發症和護理複雜性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章糖尿病腎臟病變治療市場：依治療類型

  • 介紹
  • 末期腎功能衰竭（ESRD）的治療
    • 腎臟透析
    • 移植
  • 藥品
    • 血管收縮素2 受體阻斷劑 (ARB)
    • 血管收縮素轉化酵素(ACE) 抑制劑
    • 降低膽固醇藥物
    • Metformin
  • 藥物治療

第7章 糖尿病腎臟病變治療市場：依最終使用者分類

  • 介紹
  • 醫院
  • 腎臟內科門診

第8章北美及南美糖尿病腎臟病變治療市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太糖尿病腎臟病變治療市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲糖尿病腎臟病變治療市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • ChemoCentryx, Inc.
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo International PLC
  • IQVIA Inc.
  • Johnson & Johnson Services, Inc.
  • Mallinckrodt Pharmaceuticals
  • Merck & Co., Inc.
  • Mesoblast Ltd
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Reata Pharmaceuticals, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-2A0283E25691

The Diabetic Nephropathy Treatment Market was valued at USD 2.26 billion in 2023, expected to reach USD 2.38 billion in 2024, and is projected to grow at a CAGR of 5.46%, to USD 3.28 billion by 2030.

Diabetic nephropathy treatment encompasses a range of therapeutics aimed at managing the complications of kidney damage due to diabetes, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and sodium-glucose co-transporter-2 (SGLT2) inhibitors. The necessity for these treatments arises from the increasing prevalence of diabetes globally, prompting a significant demand for effective interventions to prevent the progression to end-stage renal disease. Key applications include reducing proteinuria, slowing renal function decline, and managing associated comorbidities. End-users predominantly comprise hospitals, nephrology clinics, and research institutes. The market is chiefly influenced by the growing diabetic population, advancements in drug development, and an increasing focus on early diagnostics. Novel biologics and precision medicine represent significant opportunities, driven by emerging insights into disease pathophysiology and genetic predispositions. However, limitations include the high cost of treatment, potential side effects, and complex regulatory procedures. Market growth is also challenged by varying healthcare systems and accessibility issues in lower-income regions. Innovation can thrive in developing patient-friendly formulations, like once-weekly oral drugs, and integrating digital health solutions for real-time patient monitoring. Additionally, research into combination therapies targeting multiple pathways could potentially enhance therapeutic efficacy. The nature of the market is highly dynamic and competitive, with major pharmaceutical companies prioritizing R&D to maintain competitive advantage. Strategically, collaborations and partnerships for research and clinical trials could be pivotal in overcoming existing challenges and accessing untapped markets. By focusing on patient-centric advancements and harnessing technological integrations, businesses can position themselves advantageously in the diabetic nephropathy treatment landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 2.26 billion
Estimated Year [2024] USD 2.38 billion
Forecast Year [2030] USD 3.28 billion
CAGR (%) 5.46%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diabetic Nephropathy Treatment Market

The Diabetic Nephropathy Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising global prevalence of diabetes with increasing geriatric population
    • Government-led initiatives to address the burden of diabetes and its complications
    • Growing emphasis on patient-centric care plans for diabetic nephropathy
  • Market Restraints
    • High cost of diabetic nephropathy treatments
  • Market Opportunities
    • Introduction of new and more effective diabetic nephropathy treatments
    • Improved reimbursement policies and healthcare coverage for diabetic nephropathy treatments
  • Market Challenges
    • Comorbidities and complexity of care associated with diabetic nephropathy

Porter's Five Forces: A Strategic Tool for Navigating the Diabetic Nephropathy Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diabetic Nephropathy Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diabetic Nephropathy Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diabetic Nephropathy Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diabetic Nephropathy Treatment Market

A detailed market share analysis in the Diabetic Nephropathy Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diabetic Nephropathy Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diabetic Nephropathy Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Diabetic Nephropathy Treatment Market

A strategic analysis of the Diabetic Nephropathy Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Diabetic Nephropathy Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, ChemoCentryx, Inc., Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Endo International PLC, IQVIA Inc., Johnson & Johnson Services, Inc., Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Mesoblast Ltd, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Reata Pharmaceuticals, Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Diabetic Nephropathy Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across End-stage Renal Disease (ESRD) Treatment, Medications, and Pharmacological Treatment. The End-stage Renal Disease (ESRD) Treatment is further studied across Kidney Dialysis and Transplant. The Medications is further studied across Angiotensin 2 Receptor Blockers (ARBs), Angiotensin-converting Enzyme (ACE) Inhibitors, Cholesterol-lowering Drugs, and Metformin.
  • Based on End-User, market is studied across Hospitals and Nephrology Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising global prevalence of diabetes with increasing geriatric population
      • 5.1.1.2. Government-led initiatives to address the burden of diabetes and its complications
      • 5.1.1.3. Growing emphasis on patient-centric care plans for diabetic nephropathy
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of diabetic nephropathy treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of new and more effective diabetic nephropathy treatments
      • 5.1.3.2. Improved reimbursement policies and healthcare coverage for diabetic nephropathy treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Comorbidities and complexity of care associated with diabetic nephropathy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Diabetic Nephropathy Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. End-stage Renal Disease (ESRD) Treatment
    • 6.2.1. Kidney Dialysis
    • 6.2.2. Transplant
  • 6.3. Medications
    • 6.3.1. Angiotensin 2 Receptor Blockers (ARBs)
    • 6.3.2. Angiotensin-converting Enzyme (ACE) Inhibitors
    • 6.3.3. Cholesterol-lowering Drugs
    • 6.3.4. Metformin
  • 6.4. Pharmacological Treatment

7. Diabetic Nephropathy Treatment Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Nephrology Clinics

8. Americas Diabetic Nephropathy Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Diabetic Nephropathy Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Diabetic Nephropathy Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. Aurobindo Pharma Limited
  • 6. Bayer AG
  • 7. Boehringer Ingelheim International GmbH
  • 8. Bristol-Myers Squibb Company
  • 9. ChemoCentryx, Inc.
  • 10. Daiichi Sankyo Company, Limited
  • 11. Dr. Reddy's Laboratories Ltd.
  • 12. Eli Lilly and Company
  • 13. Endo International PLC
  • 14. IQVIA Inc.
  • 15. Johnson & Johnson Services, Inc.
  • 16. Mallinckrodt Pharmaceuticals
  • 17. Merck & Co., Inc.
  • 18. Mesoblast Ltd
  • 19. Novartis AG
  • 20. Otsuka Pharmaceutical Co., Ltd.
  • 21. Pfizer, Inc.
  • 22. Reata Pharmaceuticals, Inc.
  • 23. Sanofi SA
  • 24. Sun Pharmaceutical Industries Ltd.
  • 25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. DIABETIC NEPHROPATHY TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. DIABETIC NEPHROPATHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. DIABETIC NEPHROPATHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIABETIC NEPHROPATHY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DIABETIC NEPHROPATHY TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY KIDNEY DIALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY ANGIOTENSIN 2 RECEPTOR BLOCKERS (ARBS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY CHOLESTEROL-LOWERING DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY METFORMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY NEPHROLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. DIABETIC NEPHROPATHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. DIABETIC NEPHROPATHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023